why choose us

First received: April 07, 2023

Clinical Trial: Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Castration-resistant Prostate Cancer

Study Type: INTERVENTIONAL


Official Title: Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)

Brief Summary: The SPECTacular study will enroll patients who are already undergoing a FDA approved PSMA-targeted Radioligand treatment cycle.During each treatment cycle, patients will receive 5 additional SPECT/CT scans to investigate the limits of agreement between dosimetry (absorbed radiation dose) approximation methods and dosimetry using the triexponential fitting method.

Read more